瞿冷之
Lv3
258 积分
2021-05-14 加入
-
Breast cancer
5天前
已完结
-
Beyond immune checkpoint blockade: emerging immunological strategies
9天前
已完结
-
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
10天前
已完结
-
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
10天前
已完结
-
Multicenter Phase II Trial of Weekly Paclitaxel in Women With Metastatic Breast Cancer
10天前
已完结
-
Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer
10天前
已完结
-
Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial
10天前
已完结
-
Natural killer cell therapies
18天前
已完结
-
NK cells for cancer immunotherapy
19天前
已完结
-
The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC)
19天前
已完结